131 related articles for article (PubMed ID: 36196369)
1. Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Schwartz S; Patel N; Longmire T; Jayaraman P; Jiang X; Lu H; Baker L; Velez J; Ramesh R; Wavreille AS; Verneret M; Fan H; Hu T; Xu F; Taraszka J; Pelletier M; Miyashiro J; Rinne M; Dranoff G; Sabatos-Peyton C; Cremasco V
Immunother Adv; 2022; 2(1):ltac019. PubMed ID: 36196369
[TBL] [Abstract][Full Text] [Related]
2. TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
Barth S; Naran K
Immunother Adv; 2022; 2(1):ltac021. PubMed ID: 36406467
[TBL] [Abstract][Full Text] [Related]
3. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.
Curigliano G; Gelderblom H; Mach N; Doi T; Tai D; Forde PM; Sarantopoulos J; Bedard PL; Lin CC; Hodi FS; Wilgenhof S; Santoro A; Sabatos-Peyton CA; Longmire TA; Xyrafas A; Sun H; Gutzwiller S; Manenti L; Naing A
Clin Cancer Res; 2021 Jul; 27(13):3620-3629. PubMed ID: 33883177
[TBL] [Abstract][Full Text] [Related]
4. Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors.
Xu S; Zhang N; Rinne ML; Sun H; Stein AM
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1653-1665. PubMed ID: 37186155
[TBL] [Abstract][Full Text] [Related]
5. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2.
Zeidan AM; Giagounidis A; Sekeres MA; Xiao Z; Sanz GF; Hoef MV; Ma F; Hertle S; Santini V
Future Oncol; 2023 Mar; 19(9):631-642. PubMed ID: 37083373
[TBL] [Abstract][Full Text] [Related]
6. Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor.
Immunother Adv; 2023; 3(1):ltad002. PubMed ID: 36819977
[TBL] [Abstract][Full Text] [Related]
7. A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy.
Kuang Z; Li L; Zhang P; Chen B; Wu M; Ni H; Yi S; Zou J; Liu J
Antib Ther; 2020 Dec; 3(4):227-236. PubMed ID: 33928230
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of M6903, an antagonistic anti-TIM-3 monoclonal antibody.
Zhang D; Jiang F; Zaynagetdinov R; Huang H; Sood VD; Wang H; Zhao X; Jenkins MH; Ji Q; Wang Y; Nannemann DP; Musil D; Wesolowski J; Paoletti A; Bartholomew T; Derner MG; An Q; Iffland C; Halle JP
Oncoimmunology; 2020; 9(1):1744921. PubMed ID: 32313722
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Human and Murine T-Cell Immunoglobulin Mucin Domain 4 (TIM-4) IgV Domain Residues Critical for Ebola Virus Entry.
Rhein BA; Brouillette RB; Schaack GA; Chiorini JA; Maury W
J Virol; 2016 Jul; 90(13):6097-6111. PubMed ID: 27122575
[TBL] [Abstract][Full Text] [Related]
10. New Checkpoint Inhibitors on the Road: Targeting TIM-3 in Solid Tumors.
Gomes de Morais AL; Cerdá S; de Miguel M
Curr Oncol Rep; 2022 May; 24(5):651-658. PubMed ID: 35218498
[TBL] [Abstract][Full Text] [Related]
11. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma.
Li H; Wu K; Tao K; Chen L; Zheng Q; Lu X; Liu J; Shi L; Liu C; Wang G; Zou W
Hepatology; 2012 Oct; 56(4):1342-51. PubMed ID: 22505239
[TBL] [Abstract][Full Text] [Related]
12. Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes.
Asayama T; Tamura H; Ishibashi M; Kuribayashi-Hamada Y; Onodera-Kondo A; Okuyama N; Yamada A; Shimizu M; Moriya K; Takahashi H; Inokuchi K
Oncotarget; 2017 Oct; 8(51):88904-88917. PubMed ID: 29179486
[TBL] [Abstract][Full Text] [Related]
13. Characterizing functional domains for TIM-mediated enveloped virus entry.
Moller-Tank S; Albritton LM; Rennert PD; Maury W
J Virol; 2014 Jun; 88(12):6702-13. PubMed ID: 24696470
[TBL] [Abstract][Full Text] [Related]
14. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells.
Lee WS; Ye Z; Cheung AMS; Goh YPS; Oh HLJ; Rajarethinam R; Yeo SP; Soh MK; Chan EHL; Tan LK; Tan SY; Chuah C; Chng WJ; Connolly JE; Wang CI
Mol Cancer Ther; 2021 Sep; 20(9):1702-1712. PubMed ID: 34158344
[TBL] [Abstract][Full Text] [Related]
15. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells.
DeKruyff RH; Bu X; Ballesteros A; Santiago C; Chim YL; Lee HH; Karisola P; Pichavant M; Kaplan GG; Umetsu DT; Freeman GJ; Casasnovas JM
J Immunol; 2010 Feb; 184(4):1918-30. PubMed ID: 20083673
[TBL] [Abstract][Full Text] [Related]
16. Establishment of novel anti-TIM-3 antibodies interfering with its binding to ligands.
Yan Z; Ma T; Wang X; Yi L; Wei P; Zhang H; Wang J
Heliyon; 2024 Apr; 10(7):e28126. PubMed ID: 38560237
[TBL] [Abstract][Full Text] [Related]
17. Leishmania donovani Impedes Antileishmanial Immunity by Suppressing Dendritic Cells via the TIM-3 Receptor.
Akhtar MN; Kumar S; Sen P
mBio; 2022 Aug; 13(4):e0330921. PubMed ID: 35924848
[TBL] [Abstract][Full Text] [Related]
18. Structure and Functions of T-cell Immunoglobulin-domain and Mucin- domain Protein 3 in Cancer.
Lu X
Curr Med Chem; 2022; 29(11):1851-1865. PubMed ID: 34365943
[TBL] [Abstract][Full Text] [Related]
19. Tim-3 blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV+ patients.
Sada-Ovalle I; Ocaña-Guzman R; Pérez-Patrigeón S; Chávez-Galán L; Sierra-Madero J; Torre-Bouscoulet L; Addo MM
J Int AIDS Soc; 2015; 18(1):20078. PubMed ID: 26486200
[TBL] [Abstract][Full Text] [Related]
20. Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes.
Kanzaki M; Wada J; Sugiyama K; Nakatsuka A; Teshigawara S; Murakami K; Inoue K; Terami T; Katayama A; Eguchi J; Akiba H; Yagita H; Makino H
Endocrinology; 2012 Feb; 153(2):612-20. PubMed ID: 22186414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
